Cities join forces for stroke care improvements
Learn how Angels Cities unite to swiftly address stroke symptoms. Quick collaboration saves crucial minutes, minimizing stroke’s devastating effects.
Search
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
The GPP Forum
The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Introducing CIAS
Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
Circular economy
Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
Purpose Hero Video
Begin a career with purpose and explore careers at Boehringer Ingelheim.
Boehringer Ingelheim Business Services Philippines Inc. | Careers
Boehringer Ingelheim Business Services Philippines Inc. | Careers
The Unwearable Collection - The GPP patient experience
The Unwearable Collection™ is a fashion line based on the experiences of patients living with generalized pustular psoriasis, designed by Bart Hess.
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Christian Betz
Prioritizing development with Christian Betz
Anna Mezentseva
Prioritizing development with Anna Mezentseva